Latest Financials News

Metals X reported a 16.6% decline in tin production at its Renison operation for Q3 2025 due to equipment and processing challenges, while cash reserves rose to $279.5 million. The company continues advancing its Rentails project and maintains strategic investments.

Dreadnought Resources has upgraded its scoping study for the Star of Mangaroon gold project, increasing the initial production target by 24% to approximately 24,700 ounces at 8.3 g/t gold, while halving the maximum cash drawdown to $5.4 million.

Equatorial Resources reports a postponed arbitration hearing over Congo iron ore disputes and seeks clarity on Guinea permit cancellations, while maintaining a solid cash reserve.

Amplia Therapeutics reports encouraging interim results for narmafotinib in metastatic pancreatic cancer, alongside a successful capital raise and key patent allowance.

Rhythm Biosciences reports strong Q1 FY26 progress, securing strategic partnerships and advancing commercial readiness for its ColoSTAT® colorectal cancer test alongside robust growth in its geneType platform.

Adslot Ltd reports solid progress in Q1 FY26, highlighting growth in its StoreFront and Marketplace platforms alongside a successful $989,000 capital raise to fuel expansion.

Tyranna Resources has advanced its exploration and acquisition efforts in Angola, securing a major stake in the Chinguar Gold Project and extending its lithium-caesium project tenure, supported by a solid cash position.

Latrobe Magnesium successfully commissioned its Demonstration Plant producing magnesium oxide and secured $10 million in funding, while receiving a $200 million financing interest from the U.S. Export Import Bank for its next-stage commercial plant.

INOVIQ Limited has raised $9.5 million to advance its pioneering ovarian cancer screening test and CAR-exosome therapeutic programs, backed by strong preclinical data and strategic partnerships.

Orthocell has appointed MontsMed as the exclusive distributor for its nerve repair product Remplir™ in Hong Kong, marking a significant step in its Asian commercialisation strategy. This move opens access to the vast Guangdong-Hong Kong-Macao Greater Bay Area, complementing existing operations in Singapore and planned expansion in Thailand.

LTR Pharma has made significant strides towards its US market debut with ROXUS, bolstered by expert appointments and peer-reviewed clinical data validating its rapid-onset ED treatments.

Carlton Investments reported a slight rise in net profit and an 8.7% increase in dividends for FY2025, while its investment portfolio grew nearly 60% over five years despite recent market fluctuations.